Diabetes is a disease in which the body either doesn't make enough insulin or can't utilize the produced insulin. Indiabetesblood glucose level is high. Polyuria, polydipsia, polyphagia, dry skin and tingling sensation in hands or feet are symptoms of diabetes. There are three types of diabetes, namely, type 1 (insulin dependent), type 2 diabetes (insulin independent) and gestational diabetes. In type 1 diabetes, the part of pancreas is attacked by body’s immune system. By mistake, the immune system destroys isletsin the pancreas assuming them as foreign particles. The islets are the insulin producing cells. Causes for type 1 diabetes are diseases of the pancreas, infections and family history. In type 2 diabetes, insulin is produced in less quantity but it’s not enough to maintain optimum blood glucose. Causes of type 2 diabetes are obesity or overweight, ethnicity, gestational diabetes, age, sedentary lifestyle, impaired glucose tolerance, family history and insulin resistance. Gestational diabetes develops only during pregnancy.
Diabetes is controlled by delivering insulin or with the help of antidiabetic drugs. Insulin is released by the beta cells in response to the high blood glucose levels. Insulin thus allows maintenance of blood glucose level in optimum range. In type 1-diabetes, the body no longer produces enough insulin as beta cells are destroyed. Thus controlling the blood sugar level is challenging aspect in management of type 1 diabetes. In such a case smart insulin can be used. A perfect glucose control will be maintained by smart insulin. Smart insulin or glucose responsive insulin has ability to circulate in the body. It would respond automatically to level of blood glucose in the body. It can turn on when it’s needed and off when it’s not needed. If the blood glucose is higher, more insulin will be released or activated. If the blood glucose level is lower, less insulin will be released. Smart insulin will avoid the complications related to high and low blood sugar levels. It will reduce the requirement of checking the blood glucose level regularly. It will also reduce the efforts of calculating insulin doses and multiple daily injections. Smart insulin will give confidence to type 1 diabetes patients, that to cover their needs for the day they have enough insulin no matter how rigorously they work, what or how stressed they are.
The major driving factor for the smart insulin market is increase in diabetic population. For instance, according to IDF, in 2015, diabetes affected 415 million people worldwide and this number is expected to reach up to 642 million by 2040. Moreover, it was found that one in 11 adults was suffering from diabetes. Moreover, rise in the collaboration of companies with research institutions will further drive this market. For instance in March 2016, JDRF and Sanofi announced expansion of their joint research collaboration to include development of glucose responsive insulin therapies for treatment of insulin dependent diabetes. The aim of this collaboration is to design therapeutic insulin which gets activated when blood-glucose levels rise and deactivated when blood-glucose levels begin to go low, thus preventing dangerous highs and lows. Moreover, technological improvements in the insulin delivery devices will also contribute to growth of this market. Further, insulin injections are painful and thus there is a rise in demand by people for alternatives such as smart insulin. This demand will boost the smart insulin market. Furthermore, smart insulin patch will serve as an opportunity for this market. The smart insulin patch will use painless microneedles to recognize the low oxygen environment which will be created when glucose levels rise. Further, it will deliver insulin as required. However, more complexities are associated in manufacturing of smart insulin which will impede the growth of smart insulin market. Moreover, huge investment cost in developing smart insulin andstrict regulatory requirements for approvalswill also hamper the growth of this market.
The key strategy followed by the major companies is acquisition to be a pioneer in this market, as smart insulin is a new market and players are looking to gain competitive advantage. For instance, in 2016, Eli Lilly and Company acquired Glycostasis, Inc. Glycostasis, Inc. invented a new technology known as smart insulin. This technology will help in regulating blood glucose level by releasing more insulin when blood glucose level is high and less insulin when blood glucose level is low. By this acquisition, Eli Lilly and Companywill become a pioneer in the smart insulin or glucose responsive insulin market.
The major players inthe smart insulin or glucose responsive insulin market are Sanofi, Novo Nordisk A/S, Juvenile Diabetes Research Foundation Ltd., Eli Lilly and Company, and Merck & Co., Inc.
Smart Insulin or Glucose Responsive Market Segmentation:
- Intermediate Acting
- Short Acting
- Premixed Type
- Long Acting
- Rapid Acting
- Type 1 Diabetes
- Type 2 Diabetes
By Delivery Device:
- Smart Insulin Patch or Microneedle Array Patch
- Smart Insulin Pen
- Smart Insulin Pump
- Rest of Europe
- South Korea
- Rest of Asia-Pacific
- South Africa
- Saudi Arabia
- United Arab Emirates
We use both primary as well as secondary research for our market surveys, estimates and for developing forecast. Our research process commence by analyzing the problem which enable us to design the scope for our research study. Our research process is uniquely designed with enough flexibility to adjust according to changing nature of products and markets, while retaining core element to ensure reliability and accuracy in research findings. We understand both macro and micro-economic factors to evaluate and forecast different market segments.
Data is extensively collected through various secondary sources such as annual reports, investor presentations, SEC filings, and other corporate publications. We also refer trade magazines, technical journals, paid databases such as Factiva and Bloomberg, industry trade journals, scientific journals, and social media data to understand market dynamics and industry trends. Further, we also conduct primary research to understand market drivers, restraints, opportunities, challenges, and competitive scenario to build our analysis.
Data Collection Matrix
Data Collection Matrix
Primary Data Sources
- Distributors & Wholesalers
- Healthcare Providers
Secondary Data Sources
- Annual Reports/SEC Filings/ Investor Presentations/ Press Releases
- Government/Associations Publications
- Case Studies
- Reference Customers
Market Modeling and Forecasting
We use epidemiology and capital equipment-based models to forecast market size of different segments at country and regional level.
- Epidemiology-based Forecasting Model: This method uses epidemiology data gathered through various publications and from physicians to estimate population of patients, flow of treatment of individual disease and therapies. The data collected through this method includes statics on incidence of disease, population suffering from disease, and treatment population. This method is used to understand:
- Number of patients for particular device or medical procedure and
- Repeated use of particular device depending on health and condition of patient
- Capital-based Forecasting Model: This method of forecasting is based on number of replacements, installed-based and new sales of capital equipment used in various healthcare and diagnostic centers. These three parameters are calculated and forecast is developed. Installation base is calculated as average number of units per facility; while sales for particular year is calculated from number of new and replace units. Secondary data is collected through various supply chain intermediaries and opinion leaders to arrive at installation and sales rate. These techniques help our analysts in validating market and developed market estimates and forecast.
We do forecast on basis of several parameters such as market drivers, market opportunities, industry trends government regulations, raw materials supply and trade dynamics to ensure relevance of forecast with market scenario. With increasing need to granulized information, we used bottom-up methodology for forecasting where we evaluate each regional segment differently and combined all forecast to develop final market forecast.
We believe primary research is a very important tool in analyzing and forecasting different markets. In order to make sure accuracy of our findings, our team conducts primary interviews at every stage of research to gain deep insights into current business environment and future trends and key developments in market. This includes use of various methods such as telephonic interviews, focus groups, face to face interviews and questionnaires to validate our research from all aspects. We validate our data through primary research from key industry leaders such as CEO, product managers, marketing managers, suppliers, distributors, and consumers are frequently interviewed. These interviews provide valuable insights which help us to have better market understanding besides validating our estimates and forecast.
Quantitative Data (2017-2025)
- Market Dynamics (Drivers, Restraints, and Challenges)
- Industry Trend Analysis
- Market Opportunities
- Government Policies and Regulations, Patent Analysis, and Reimbursement Policies
- Porter’s Five Forces and PESTLE Analysis
- Key Developments and Competitive Landscape
- Market Assessment and Forecast
- Market Assessment and Forecast, By Product
- Market Assessment and Forecast, By Technology
- Market Assessment and Forecast, By Application
- Market Assessment and Forecast, By End User
- Market Assessment and Forecast, By Region/Country